AbbVie Inc. $ABBV Shares Bought by Eastern Bank

Eastern Bank grew its holdings in AbbVie Inc. (NYSE:ABBV) by 0.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 380,469 shares of the company’s stock after purchasing an additional 2,481 shares during the quarter. AbbVie makes up about 1.5% of Eastern Bank’s portfolio, making the stock its 18th biggest holding. Eastern Bank’s holdings in AbbVie were worth $86,933,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Randall & Associates Wealth Management acquired a new stake in AbbVie in the 4th quarter valued at $298,000. Woodward Diversified Capital LLC lifted its stake in shares of AbbVie by 3.3% during the fourth quarter. Woodward Diversified Capital LLC now owns 9,300 shares of the company’s stock worth $2,125,000 after purchasing an additional 297 shares in the last quarter. Terra Nova Asset Management LLC lifted its stake in shares of AbbVie by 31.2% during the fourth quarter. Terra Nova Asset Management LLC now owns 2,526 shares of the company’s stock worth $577,000 after purchasing an additional 601 shares in the last quarter. Waldron Private Wealth LLC boosted its position in shares of AbbVie by 1.8% in the fourth quarter. Waldron Private Wealth LLC now owns 29,073 shares of the company’s stock worth $6,643,000 after buying an additional 502 shares during the period. Finally, Acropolis Investment Management LLC boosted its position in shares of AbbVie by 0.9% in the fourth quarter. Acropolis Investment Management LLC now owns 7,038 shares of the company’s stock worth $1,608,000 after buying an additional 60 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on ABBV shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Barclays began coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Company outlook and dividend expectations — Analysts and commentators highlight AbbVie’s strong 2026 guidance and the likelihood of future dividend increases, driven by cash flow from Humira/Imbruvica/oncology and growth in the dermatology portfolio; that narrative supports income investors and dividend yield buyers. AbbVie: Strong 2026 Outlook, Expect Dividend Increases
• Positive Sentiment: Clinical and real‑world data boost dermatology franchise — AbbVie announced new clinical and real‑world evidence for risankizumab (psoriasis/psoriatic arthritis) and upadacitinib (atopic dermatitis), plus Phase‑3 data for vitiligo and alopecia areata to be presented at AAD 2026. Strong safety/efficacy reads can support durable revenue and reduce investor uncertainty around launches. AbbVie to Highlight New Clinical and Real-World Evidence…
• Positive Sentiment: Analyst estimate tweak — Erste Group modestly raised its FY2027 EPS estimate for AbbVie, signaling incremental confidence in earnings power (small change but supportive vs. downside fears). MarketBeat AbbVie Profile
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) scientific presence — Allergan is presenting multiple evidence‑based posters and product positioning (JUVÉDERM, HA injectables) at AMWC, reinforcing aesthetics growth and brand leadership but with limited immediate revenue impact. Allergan Aesthetics Reinforces Scientific Differentiation…
• Neutral Sentiment: Dividend yield framing for investors — Retail‑focused pieces (The Motley Fool) calculate how many ABBV shares generate targeted dividend income; useful for income investors but not an earnings catalyst. Here’s How Many Shares of AbbVie (ABBV) Stock You’d Need…
• Negative Sentiment: Recent price weakness & value debate — Coverage noting recent share‑price declines and questions about valuation may pressure sentiment in the short term; headline focus on near‑term multiple compression can spur selling even as fundamentals are debated. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

AbbVie Stock Down 0.8%

Shares of ABBV opened at $209.46 on Friday. The firm has a market cap of $370.37 billion, a price-to-earnings ratio of 88.76, a PEG ratio of 0.73 and a beta of 0.34. The business’s 50 day moving average is $221.96 and its two-hundred day moving average is $224.62. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.